Brii Biosciences
https://www.briibio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Brii Biosciences
Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE
Plus deals involving Novo Nordisk/Neomorph, Mabwell/Jiangsu Haibo, Alteogen/Merck & Co., Gilead/Biocytogen, AlphaGen/ARTBIO and XOMA/Kinnate.
Brii Ups Its Bet On VBI’s Hepatitis B Assets Amid Larger Treatment, Prevention Push
The two companies have partnered on VBI-2601 since 2018, and Brii is now taking global rights to that program as well as licensing rights to VBI’s hepatitis B vaccine.
Creating Best In Class Antivirals In Post-COVID China: Interview with Huahui Health CSO Li Wenhui
COVID-19 has highlighted the need for potent, safe and effective antiviral therapies for infectious diseases and now one well-known Chinese researcher is tackling hepatitis B and D though a homegrown drug discovery approach. He talks to Scrip in this wide-ranging audio interview.
Chinese Biotechs Reshuffle Pipeline, Cut Headcount To Stay Afloat
Two bioventures in China have jettisoned immuno-oncology assets, including PD-1/L1- and CD47-targeting agents, while four other firms have disclosed shifts in R&D priorities and employee lay-offs as they deal with challenging conditions.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Brii Biosciences Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice